CD40 and cancer: Agonistic mAbs that stimulate CD40 signaling are in development as cancer therapeutics designed to potentiate anti-tumor immunity (Remer et al., 2017, Vonderheide and Glennie, 2013), with the most encouraging results coming with CP870,893 in pancreatic cancer (Beatty et al., 2011).